Therapeutic potential of Fingolimod in triple negative breast cancer preclinical models

Translational Oncology - Tập 14 - Trang 100926 - 2021
Tristan Rupp1, Océane Pelouin1, Laurie Genest1, Christophe Legrand1, Guillaume Froget1, Vincent Castagné1
1Porsolt SAS, ZA de Glatigné, 53940 Le Genest-Saint-Isle, France

Tài liệu tham khảo

Cardoso, 2018, 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)†, Ann. Oncol., 29, 1634, 10.1093/annonc/mdy192

Harbeck, 2019, Breast cancer, Nat. Rev. Dis. Primers, 5, 1, 10.1038/s41572-019-0111-2

Dent, 2007, Triple-negative breast cancer: clinical features and patterns of recurrence, Clin. Cancer Res., 13, 4429, 10.1158/1078-0432.CCR-06-3045

Nagahashi, 2018, The role of sphingosine‐1‐phosphate in inflammation and cancer progression, Cancer Sci., 109, 3671, 10.1111/cas.13802

Pyne, 2010, Sphingosine 1-phosphate and cancer, Nat. Rev. Cancer, 10, 489, 10.1038/nrc2875

Grammatikos, 2016, Serum sphingolipidomic analyses reveal an upregulation of C16- ceramide and sphingosine-1-phosphate in hepatocellular carcinoma, Oncotarget, 7, 18095, 10.18632/oncotarget.7741

Zeng, 2016, Sphingosine-1-phosphate induced epithelial-mesenchymal transition of hepatocellular carcinoma via an MMP-7/syndecan-1/TGF-β autocrine loop, Oncotarget, 7, 63324, 10.18632/oncotarget.11450

Hirose, 2018, Generation of sphingosine-1-phosphate is enhanced in biliary tract cancer patients and is associated with lymphatic metastasis, Sci. Rep., 8, 10.1038/s41598-018-29144-9

Nagahashi, 2016, High levels of sphingolipids in human breast cancer, J. Surg. Res., 204, 435, 10.1016/j.jss.2016.05.022

Wang, 2018, Triple negative breast cancer depends on sphingosine kinase 1 (SphK1)/sphingosine-1-phosphate (S1P)/sphingosine 1-phosphate receptor 3 (S1PR3)/notch signaling for metastasis, Med. Sci. Monit., 24, 1912, 10.12659/MSM.905833

Tintore, 2019, Treatment of multiple sclerosis — success from bench to bedside, Nat. Rev. Neurol., 15, 53, 10.1038/s41582-018-0082-z

Geffken, 2018, Sphingosine kinase 1 in breast cancer, Adv. Biol. Regul., 67, 59, 10.1016/j.jbior.2017.10.005

Patmanathan, 2015, The antineoplastic properties of FTY720: evidence for the repurposing of Fingolimod, J. Cell. Mol. Med., 19, 2329, 10.1111/jcmm.12635

White, 2016, The emerging role of FTY720 (Fingolimod) in cancer treatment, Oncotarget, 7, 23106, 10.18632/oncotarget.7145

Rosa, 2013, Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models, Clin. Cancer Res., 19, 138, 10.1158/1078-0432.CCR-12-1050

Ho, 2005, Effects of a novel immunomodulating agent, FTY720, on tumor growth and angiogenesis in hepatocellular carcinoma, Mol. Cancer Ther., 4, 1430, 10.1158/1535-7163.MCT-05-0021

Pchejetski, 2010, FTY720 (Fingolimod) sensitizes prostate cancer cells to radiotherapy by inhibition of sphingosine kinase-1, Cancer Res., 70, 8651, 10.1158/0008-5472.CAN-10-1388

Gstalder, 2016, FTY720 (Fingolimod) inhibits HIF1 and HIF2 signaling, promotes vascular remodeling, and chemosensitizes in renal cell carcinoma animal model, Mol. Cancer Ther., 15, 2465, 10.1158/1535-7163.MCT-16-0167

LaMontagne, 2006, Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization, Cancer Res., 66, 221, 10.1158/0008-5472.CAN-05-2001

Langlois, 2014, AngioMatrix, a signature of the tumor angiogenic switch-specific matrisome, correlates with poor prognosis for glioma and colorectal cancer patients, Oncotarget, 5, 10529, 10.18632/oncotarget.2470

Rupp, 2016, Tenascin-C orchestrates glioblastoma angiogenesis by modulation of pro- and anti-angiogenic signaling, Cell Rep., 17, 2607, 10.1016/j.celrep.2016.11.012

Kalhori, 2016, FTY720 (Fingolimod) attenuates basal and sphingosine-1-phosphate-evoked thyroid cancer cell invasion, Endocr. Relat. Cancer, 23, 457, 10.1530/ERC-16-0050

Azuma, 2002, Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse breast cancer models, Cancer Res., 62, 1410

Mousseau, 2012, Fingolimod potentiates the effects of sunitinib malate in a rat breast cancer model, Breast Cancer Res. Treat., 134, 31, 10.1007/s10549-011-1903-6

Nagahashi, 2018, Targeting the SphK1/S1P/S1PR1 axis that links obesity, chronic inflammation, and breast cancer metastasis, Cancer Res., 78, 1713, 10.1158/0008-5472.CAN-17-1423

Dai, 2017, Breast cancer cell line classification and its relevance with breast tumor subtyping, J. Cancer, 8, 3131, 10.7150/jca.18457

Martin, 2017, Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade, Breast Cancer Res., 19

Liang, 2014, Silencing of CXCR4 sensitizes triple-negative breast cancer cells to cisplatin, Oncotarget, 6, 1020, 10.18632/oncotarget.2741

Gomes, 2019, ATR mediates cisplatin resistance in 3D-cultured breast cancer cells via translesion DNA synthesis modulation, Cell Death. Dis., 10, 1, 10.1038/s41419-019-1689-8

Marvaso, 2014, Sphingosine analog fingolimod (FTY720) increases radiation sensitivity of human breast cancer cells in vitro, Cancer Biol. Ther., 15, 797, 10.4161/cbt.28556

Chen, 2015, Dose-response relationship in cisplatin-treated breast cancer xenografts monitored with dynamic contrast-enhanced ultrasound, BMC Cancer, 15, 10.1186/s12885-015-1170-8

Liang, 2005, Silencing of CXCR4 Blocks Breast Cancer Metastasis, Cancer Res., 65, 967, 10.1158/0008-5472.967.65.3

Woo, 2015, FTY720 enhances TRAIL-mediated apoptosis by up-regulating DR5 and down-regulating Mcl-1 in cancer cells, Oncotarget, 6, 11614, 10.18632/oncotarget.3426

Nagahashi, 2012, Sphingosine-1-phosphate produced by sphingosine kinase 1 promotes breast cancer progression by stimulating angiogenesis and lymphangiogenesis, Cancer Res., 72, 726, 10.1158/0008-5472.CAN-11-2167

Hill, 2019, Cisplatin-resistant triple-negative breast cancer subtypes: multiple mechanisms of resistance, BMC Cancer, 19, 1039, 10.1186/s12885-019-6278-9

Hu, 2015, Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial, Lancet Oncol., 16, 436, 10.1016/S1470-2045(15)70064-1

Park, 2013, Inhibition of endotrophin, a cleavage product of collagen VI, confers cisplatin sensitivity to tumours, EMBO Mol. Med., 5, 935, 10.1002/emmm.201202006

Yu, 2016, Triple-layered pH-responsive micelleplexes loaded with siRNA and cisplatin prodrug for NF-Kappa B targeted treatment of metastatic breast cancer, Theranostics, 6, 14, 10.7150/thno.13515

Zanoni, 2016, 3D tumor spheroid models for in vitro therapeutic screening: a systematic approach to enhance the biological relevance of data obtained, Sci. Rep., 6, 19103, 10.1038/srep19103

Phung, 2011, Rapid generation of in vitro multicellular spheroids for the study of monoclonal antibody therapy, J. Cancer, 2, 507, 10.7150/jca.2.507

Sant, 2017, The production of 3D tumor spheroids for cancer drug discovery, Drug Discov. Today Technol., 23, 27, 10.1016/j.ddtec.2017.03.002

Swami, 2017, Prevention of breast cancer skeletal metastases with parathyroid hormone, JCI Insight, 2, 10.1172/jci.insight.90874

Zhang, 2015, Surgically-induced multi-organ metastasis in an orthotopic syngeneic imageable model of 4T1 murine breast cancer, Anticancer Res., 35, 4641

Cominetti, 2019, Metastasis inhibition in breast cancer by targeting cancer cell extravasation, Breast Cancer (Dove Med Press), 11, 165

Lambertini, 2019, Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: exploratory analysis of the GIM2 trial, Int. J. Cancer

Tsuchida, 2016, Breast cancer S1P is associated with pSphK1 and lymphatic metastasis, J. Surg. Res., 205, 85, 10.1016/j.jss.2016.06.022

Kreitzburg, 2018, FTY720 enhances the anti-tumor activity of carboplatin and tamoxifen in a patient-derived xenograft model of ovarian cancer, Cancer Lett., 436, 75, 10.1016/j.canlet.2018.08.015

Stafman, 2019, PP2A activation alone and in combination with cisplatin decreases cell growth and tumor formation in human HuH6 hepatoblastoma cells, PLoS One, 14, 10.1371/journal.pone.0214469

Ng, 2007, Marked suppression of tumor growth by FTY720 in a rat liver tumor model: the significance of down-regulation of cell survival Akt pathway, Int. J. Oncol., 30, 375

Siddik, 2003, Cisplatin: mode of cytotoxic action and molecular basis of resistance, Oncogene, 22, 7265, 10.1038/sj.onc.1206933

Dasari, 2014, Cisplatin in cancer therapy: molecular mechanisms of action, Eur. J. Pharmacol., 0, 364, 10.1016/j.ejphar.2014.07.025

Garner, 2018, FTY720 decreases tumorigenesis in group 3 medulloblastoma patient-derived xenografts, Sci. Rep., 8, 10.1038/s41598-018-25263-5

Chen, 2018, Inhibition of RhoA and mTORC2/Rictor by Fingolimod (FTY720) induces p21-activated kinase 1, PAK-1 and amplifies podosomes in mouse peritoneal macrophages, Immunobiology, 223, 634, 10.1016/j.imbio.2018.07.009

Zhou, 2006, FTY720, a fungus metabolite, inhibits invasion ability of androgen-independent prostate cancer cells through inactivation of RhoA-GTPase, Cancer Lett., 233, 36, 10.1016/j.canlet.2005.02.039

Lu, 2014, FTY720 inhibits proliferation and epithelial-mesenchymal transition in cholangiocarcinoma by inactivating STAT3 signaling, BMC Cancer, 14, 10.1186/1471-2407-14-783

Zhang, 2014, FTY720 reduces migration and invasion of human glioblastoma cell lines via inhibiting the PI3K/AKT/mTOR/p70S6K signaling pathway, Tumor Biol., 35, 10707, 10.1007/s13277-014-2386-y

Lee, 2005, FTY720: a promising agent for treatment of metastatic hepatocellular carcinoma, Clin. Cancer Res., 11, 8458, 10.1158/1078-0432.CCR-05-0447

Li, 2012, FTY720 suppresses liver tumor metastasis by reducing the population of circulating endothelial progenitor cells, PLoS One, 7

Pereira, 2013, FTY720 induces apoptosis in B16F10-NEX2 murine melanoma cells, limits metastatic development in vivo, and modulates the immune system, Clinics (Sao Paulo), 68, 1018, 10.6061/clinics/2013(07)21

Spitzer, 2017, Systemic immunity is required for effective cancer immunotherapy, Cell, 168, 487, 10.1016/j.cell.2016.12.022

Vishnoi, 2019, The identification of a TNBC liver metastasis gene signature by sequential CTC-xenograft modeling, Mol. Oncol., 13, 1913, 10.1002/1878-0261.12533

Koedoot, 2019, Uncovering the signaling landscape controlling breast cancer cell migration identifies novel metastasis driver genes, Nat. Commun., 10, 1, 10.1038/s41467-019-11020-3

Chen, 2018, Organotropism: new insights into molecular mechanisms of breast cancer metastasis, NPJ Precis. Oncol., 2

Tseng, 2013, Distant metastasis in triple-negative breast cancer, Neoplasma, 60, 290, 10.4149/neo_2013_038

Beider, 2017, The sphingosine-1-phosphate modulator FTY720 targets multiple myeloma via the CXCR4/CXCL12 pathway, Clin. Cancer Res., 23, 1733, 10.1158/1078-0432.CCR-15-2618

Herrmann, 2016, Identification of gene expression patterns crucially involved in experimental autoimmune encephalomyelitis and multiple sclerosis, Dis. Model. Mech., 9, 1211, 10.1242/dmm.025536

Allam, 2018, Fingolimod interrupts the cross talk between estrogen metabolism and sphingolipid metabolism within prostate cancer cells, Toxicol. Lett., 291, 77, 10.1016/j.toxlet.2018.04.008

Fujimoto, 2019, Improved prognosis of low baseline neutrophil-to-lymphocyte ratio is significantly exclusive in breast cancer patients with high absolute counts of lymphocytes, Mol. Clin. Oncol., 10, 275

Zhao, 2017, Lymphocyte count or percentage: which can better predict the prognosis of advanced cancer patients following palliative care?, BMC Cancer, 17, 514, 10.1186/s12885-017-3498-8

Spranger, 2014, Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment, J. Immunother. Cancer, 2, 3, 10.1186/2051-1426-2-3

Snelder, 2014, Translational pharmacokinetic modeling of fingolimod (FTY720) as a paradigm compound subject to sphingosine kinase-mediated phosphorylation, Drug Metab. Dispos., 42, 1367, 10.1124/dmd.113.056770

Nirogi, 2017, Incurred sample reanalysis of fingolimod and fingolimod phosphate in blood: stability evaluation and application to a rat pharmacokinetic study, Bioanalysis, 9, 565, 10.4155/bio-2016-0308

Kovarik, 2004, Multiple-Dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects, J. Clin. Pharmacol., 44, 532, 10.1177/0091270004264165

Center for Drug Evaluation and Research [CDER]. Application number: 22-527. Clinical pharmacology and biopharmaceutics review(s) [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022527Orig1s000clinpharmr.pdf [Accessed 2020 Nov 8] n.d.

Wu, 2018, Targeted co-delivery of Beclin 1 siRNA and FTY720 to hepatocellular carcinoma by calcium phosphate nanoparticles for enhanced anticancer efficacy, Int. J. Nanomed., 13, 1265, 10.2147/IJN.S156328

Galluzzi, 2012, Molecular mechanisms of cisplatin resistance, Oncogene, 31, 1869, 10.1038/onc.2011.384

Anasamy, 2020, In vivo antitumour properties of tribenzyltin carboxylates in a 4T1 murine metastatic mammary tumour model: enhanced efficacy by PLGA nanoparticles, Eur. J. Pharm. Sci., 142, 10.1016/j.ejps.2019.105140

Feng, 2015, Near infrared light-actuated gold nanorods with cisplatin-polypeptide wrapping for targeted therapy of triple negative breast cancer, Nanoscale, 7, 14854, 10.1039/C5NR03693C

Yoshii, 2017, Neurological safety of fingolimod: an updated review, Clin. Exp. Neuroimmunol., 8, 233, 10.1111/cen3.12397

Hait, 2015, The phosphorylated prodrug FTY720 is a histone deacetylase inhibitor that reactivates ERα expression and enhances hormonal therapy for breast cancer, Oncogenesis, 4, e156, 10.1038/oncsis.2015.16

Thông tin
Thông tin xuất bản

Translational Oncology

Tập 14

100926

Thông tin tác giả